Legislative & Regulatory Updates
How the Anticipated Rescheduling of Cannabis and its Effects on 280E Reshapes Cannabis Tax Strategy
Cannabis businesses may gain access to tax deductions and strategies long restricted under federal law. This shift requires careful reassessment of cash flow, accounting positions, and long-term planning to leverage new flexibility. Key Takeaways: For years, Section 280E has shaped nearly every financial decision cannabis operators make. It dictates how taxes are calculated, how cash […]
Cannabis Rescheduling to Schedule III: What It Means for Cannabis Businesses
The U.S. Department of Justice has begun the long-anticipated shift of cannabis from Schedule I to Schedule III under the Controlled Substances Act. The action follows a presidential directive issued late last year and marks a notable change in how federal regulators approach cannabis, particularly in the context of medical use, research, and taxation. The […]
What Businesses Should Know About the New Overtime Deduction
The Department of the Treasury and the Internal Revenue Service issued new guidance on a deduction tied to overtime pay under the One Big Beautiful Bill Act. The newly released IRS FAQs clarify how the deduction works, confirm transitional relief for 2025, and identify where employees should look for authoritative information. Understanding those boundaries may […]
IRS Updates Guidance on Business Interest Deductions
Key takeaways: The Internal Revenue Service recently clarified its Section 163(j) FAQs following changes under the One Big Beautiful Bill Act. These updates do not create new law but provide practical guidance for companies evaluating financing, merger and acquisitions activity, or capital investments. For businesses with significant depreciation or amortization, the revised framework helps align […]
Executive Order to Reschedule Cannabis: What It Means for IRC 280E
On December 18, 2025, President Trump issued an Executive Order directing the Department of Justice (DOJ) to expedite the rescheduling of cannabis to Schedule III under the Controlled Substances Act (CSA). This action follows the Department of Health and Human Services’ (HHS) 2023 recommendation and represents a major turning point for state-legal cannabis businesses. Why […]
Cannabis Rescheduling: What It Means for Operators and Investors—and How We’ll Help You Navigate It
The federal government’s anticipated move to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act is one of the most consequential policy shifts the industry has seen to date. While this change may promise tax relief, expanded research opportunities, and improved access to capital, it also likely introduces stricter federal oversight […]
Understanding the One Big Beautiful Bill’s Effects on Nonprofits
On July 4, 2025, President Trump signed into law H.R.1, commonly known as the One Big Beautiful Bill (OBBB) Act. The legislation includes several provisions that may affect charitable organizations. Corporate Giving Floor. Under the OBBB, corporations can claim a charitable deduction only if contributions exceed one percent of taxable income. Corporations may carry forward […]
Positive Changes for R&E Tax Deductions Under OBBB
For decades, companies have navigated the complexities involved in deducting research and experimental expenditures. The One Big Beautiful Bill (OBBB) Act with the newly released Revenue Procedure 2025-28 changes that landscape. Starting with tax years after December 31, 2024, domestic research and development expenses may be deducted immediately, replacing the prior five-year capitalization and amortization […]
Life Sciences Gain R&D Tax Relief Under OBBB
Life sciences companies face some of the highest costs and longest timelines for research and development. The One Big Beautiful Bill (OBBB) Act, with the newly released IRS Revenue Procedure 2025-28, eases some of the tax complexity around these expenditures. Starting with tax years after December 31, 2024, domestic research and development expenses may be […]